Ascentage Pharma announced on July 17, 2025, the successful closing of its offshore top-up placement. This transaction resulted in net proceeds to the company of approximately HKD1,492 million, equivalent to about US$190.1 million.
The placement involved the sale of 22 million ordinary shares by Dajun Yang Dynasty Trust, an affiliate of the company’s CEO, followed by the company issuing 22 million new ordinary shares to the Vendor at HKD68.60 per share. The newly issued equity represents approximately 6.29% of the company’s issued share capital prior to the placement.
These proceeds are earmarked for critical strategic areas, including expanding commercialization efforts, advancing global clinical development for core pipeline candidates, and strengthening infrastructure and working capital. This capital infusion significantly enhances Ascentage Pharma's financial runway to execute its growth plans.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.